药代-话题@MedSci

#药代#

158篇内容 | 1438人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1666752, encodeId=188f1666e5245, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=医药代表：拜访受限的应对策略与关键行动计划, objectType=article, longId=187884, objectId=76b118e8848c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76b118e8848c, replyNumber=0, likeNumber=42, createdTime=2020-10-22, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76b118e8848c, moduleTitle=医药代表：拜访受限的应对策略与关键行动计划, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76b118e8848c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666758, encodeId=61eb1666e58fd, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=不得担任销售，必须备案！300万医药代表迎来大整顿, objectType=article, longId=196128, objectId=4e1e19612876, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e1e19612876, replyNumber=0, likeNumber=27, createdTime=2021-01-13, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e1e19612876, moduleTitle=不得担任销售，必须备案！300万医药代表迎来大整顿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e1e19612876)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666757, encodeId=d3eb1666e57e3, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=Andrology：一代磷酸二酯酶5抑制剂及其药代动力学问题, objectType=article, longId=192978, objectId=ed8c1929e84e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed8c1929e84e, replyNumber=0, likeNumber=26, createdTime=2021-04-09, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed8c1929e84e, moduleTitle=Andrology：一代磷酸二酯酶5抑制剂及其药代动力学问题, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed8c1929e84e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666746, encodeId=cdc71666e46aa, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=两三甲医院，通知医药代表备案, objectType=article, longId=181937, objectId=5dda18193e40, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5dda18193e40, replyNumber=0, likeNumber=39, createdTime=2020-08-17, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5dda18193e40, moduleTitle=两三甲医院，通知医药代表备案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5dda18193e40)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666759, encodeId=ecb11666e597b, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=Biomed Chromatogr：知柏草煎剂口服后八种生物活性成分的药代动力学研究及临床疗效观察, objectType=article, longId=197209, objectId=9f5919e209b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f5919e209b8, replyNumber=0, likeNumber=34, createdTime=2020-10-15, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f5919e209b8, moduleTitle=Biomed Chromatogr：知柏草煎剂口服后八种生物活性成分的药代动力学研究及临床疗效观察, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f5919e209b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666748, encodeId=efe51666e48b7, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=医药代表备案证件，重要信息公开了, objectType=article, longId=183177, objectId=ce1c1831e769, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce1c1831e769, replyNumber=0, likeNumber=32, createdTime=2020-01-10, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce1c1831e769, moduleTitle=医药代表备案证件，重要信息公开了, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce1c1831e769)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666738, encodeId=bdc31666e3818, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=日本发布《2019年医药代表白皮书》, objectType=article, longId=178498, objectId=5a471e849894, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a471e849894, replyNumber=0, likeNumber=32, createdTime=2020-06-19, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a471e849894, moduleTitle=日本发布《2019年医药代表白皮书》, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a471e849894)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666743, encodeId=91f21666e435c, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=2019药代现状：老代表越来越少, objectType=article, longId=180722, objectId=9a9c180e22ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a9c180e22ff, replyNumber=0, likeNumber=34, createdTime=2020-06-07, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a9c180e22ff, moduleTitle=2019药代现状：老代表越来越少, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a9c180e22ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666755, encodeId=b4741666e559a, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=Respir Investig：贝达喹啉在日本耐肺多药结核病患者中的安全性，有效性和药代动力学, objectType=article, longId=192368, objectId=f90c192368f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f90c192368f9, replyNumber=0, likeNumber=30, createdTime=2020-07-11, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f90c192368f9, moduleTitle=Respir Investig：贝达喹啉在日本耐肺多药结核病患者中的安全性，有效性和药代动力学, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f90c192368f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666750, encodeId=5f841666e5076, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=央视：60名医药代表被捕, objectType=article, longId=186497, objectId=c9ba18649eb8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9ba18649eb8, replyNumber=0, likeNumber=37, createdTime=2020-08-11, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9ba18649eb8, moduleTitle=央视：60名医药代表被捕, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c9ba18649eb8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666756, encodeId=f7bd1666e56c3, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=Blood：口服cedazuridine/地西他滨治疗MDS和CMML的药代动力学、疗效和安全性, objectType=article, longId=192727, objectId=297f192e2779, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=297f192e2779, replyNumber=0, likeNumber=37, createdTime=2020-11-15, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=297f192e2779, moduleTitle=Blood：口服cedazuridine/地西他滨治疗MDS和CMML的药代动力学、疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=297f192e2779)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666753, encodeId=70e11666e53f2, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=AP&T：二甲双胍在慢性肝病患者中的安全性和药代动力学, objectType=article, longId=188221, objectId=2cdc188221b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cdc188221b6, replyNumber=0, likeNumber=35, createdTime=2021-01-14, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cdc188221b6, moduleTitle=AP&T：二甲双胍在慢性肝病患者中的安全性和药代动力学, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cdc188221b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666732, encodeId=314f1666e329a, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=医院下令“画像”驱逐！药代究竟该怎样活下去？, objectType=article, longId=168138, objectId=34b1168138bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34b1168138bd, replyNumber=0, likeNumber=23, createdTime=2019-09-29, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34b1168138bd, moduleTitle=医院下令“画像”驱逐！药代究竟该怎样活下去？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34b1168138bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666733, encodeId=aa821666e339a, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=Clin Gastroenterology H：英夫利昔单抗和硫唑嘌呤联合治疗可改善英夫利昔单药代动力学特征和疗效, objectType=article, longId=175464, objectId=2f6d1e546456, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f6d1e546456, replyNumber=0, likeNumber=27, createdTime=2020-06-13, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f6d1e546456, moduleTitle=Clin Gastroenterology H：英夫利昔单抗和硫唑嘌呤联合治疗可改善英夫利昔单药代动力学特征和疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f6d1e546456)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666736, encodeId=3dee1666e3638, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=一位日本医药代表的一天, objectType=article, longId=176737, objectId=aff61e673765, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aff61e673765, replyNumber=0, likeNumber=30, createdTime=2019-12-10, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aff61e673765, moduleTitle=一位日本医药代表的一天, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aff61e673765)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666751, encodeId=a8dd1666e5185, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=2020医药代表年度报告, objectType=article, longId=186498, objectId=b23618649877, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b23618649877, replyNumber=0, likeNumber=29, createdTime=2020-07-21, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b23618649877, moduleTitle=2020医药代表年度报告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b23618649877)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666742, encodeId=65471666e4250, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=药品集采扩面之后，医药代表的战略价值, objectType=article, longId=180249, objectId=2ae318024955, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ae318024955, replyNumber=0, likeNumber=46, createdTime=2019-10-04, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ae318024955, moduleTitle=药品集采扩面之后，医药代表的战略价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ae318024955)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666731, encodeId=466d1666e31ec, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=广西省严打医药购销不正之风医药代表全部备案, objectType=article, longId=168077, objectId=6aff1680e795, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6aff1680e795, replyNumber=0, likeNumber=25, createdTime=2019-10-04, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6aff1680e795, moduleTitle=广西省严打医药购销不正之风医药代表全部备案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6aff1680e795)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666744, encodeId=fc6d1666e4443, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=医药代表的收入，减少了吗？, objectType=article, longId=181062, objectId=b713181062bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b713181062bd, replyNumber=0, likeNumber=37, createdTime=2020-09-23, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b713181062bd, moduleTitle=医药代表的收入，减少了吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b713181062bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666749, encodeId=91dc1666e490d, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=一个女医药代表的行贿日记；10天内，41名医务人员主动投案！, objectType=article, longId=185357, objectId=e10918535e3a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e10918535e3a, replyNumber=0, likeNumber=41, createdTime=2020-09-10, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e10918535e3a, moduleTitle=一个女医药代表的行贿日记；10天内，41名医务人员主动投案！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e10918535e3a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

药代

2020-05-29

fengyqf (审核中...)

前往app查看评论内容

#药代#

医药代表：拜访受限的应对策略与关键行动计划

2020-10-22

fengyqf (审核中...)

前往app查看评论内容

#药代#

不得担任销售，必须备案！300万医药代表迎来大整顿

2021-01-13

fengyqf (审核中...)

前往app查看评论内容

#药代#

Andrology：一代磷酸二酯酶5抑制剂及其药代动力学问题

2021-04-09

fengyqf (审核中...)

前往app查看评论内容

#药代#

两三甲医院，通知医药代表备案

2020-08-17

fengyqf (审核中...)

前往app查看评论内容

#药代#

Biomed Chromatogr：知柏草煎剂口服后八种生物活性成分的药代动力学研究及临床疗效观察

2020-10-15

fengyqf (审核中...)

前往app查看评论内容

#药代#

医药代表备案证件，重要信息公开了

2020-01-10

fengyqf (审核中...)

前往app查看评论内容

#药代#

日本发布《2019年医药代表白皮书》

2020-06-19

fengyqf (审核中...)

前往app查看评论内容

#药代#

2019药代现状：老代表越来越少

2020-06-07

fengyqf (审核中...)

前往app查看评论内容

#药代#

Respir Investig：贝达喹啉在日本耐肺多药结核病患者中的安全性，有效性和药代动力学

2020-07-11

fengyqf (审核中...)

前往app查看评论内容

#药代#

央视：60名医药代表被捕

2020-08-11

fengyqf (审核中...)

前往app查看评论内容

#药代#

Blood：口服cedazuridine/地西他滨治疗MDS和CMML的药代动力学、疗效和安全性

2020-11-15

fengyqf (审核中...)

前往app查看评论内容

#药代#

AP&T：二甲双胍在慢性肝病患者中的安全性和药代动力学

2021-01-14

fengyqf (审核中...)

前往app查看评论内容

#药代#

医院下令“画像”驱逐！药代究竟该怎样活下去？

2019-09-29

fengyqf (审核中...)

前往app查看评论内容

#药代#

Clin Gastroenterology H：英夫利昔单抗和硫唑嘌呤联合治疗可改善英夫利昔单药代动力学特征和疗效

2020-06-13

fengyqf (审核中...)

前往app查看评论内容

#药代#

一位日本医药代表的一天

2019-12-10

fengyqf (审核中...)

前往app查看评论内容

#药代#

2020医药代表年度报告

2020-07-21

fengyqf (审核中...)

前往app查看评论内容

#药代#

药品集采扩面之后，医药代表的战略价值

2019-10-04

fengyqf (审核中...)

前往app查看评论内容

#药代#

广西省严打医药购销不正之风医药代表全部备案

2019-10-04

fengyqf (审核中...)

前往app查看评论内容

#药代#

医药代表的收入，减少了吗？

2020-09-23

fengyqf (审核中...)

前往app查看评论内容

#药代#

一个女医药代表的行贿日记；10天内，41名医务人员主动投案！

2020-09-10

科室
- - 订阅+
  - 更多科室
工具
服务